Entolimod - Statera BioPharma
Alternative Names: CBLB-502; CYTO-601; CYTO-601 ARS; CYTO-602; CYTO-602 Oncology; Entolimod™; STAT-600; STAT-601Latest Information Update: 27 May 2025
At a glance
- Originator Cleveland BioLabs
- Developer Statera BioPharma; Tivic Health
- Class Anti-ischaemics; Antidotes; Antineoplastics; Chemoprotectants; Peptides; Radioprotectives; Recombinant proteins
- Mechanism of Action Apoptosis inhibitors; NF-kappa B modulators; Toll-like receptor 5 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acute radiation syndrome
- Phase II Colorectal cancer
- Phase I Neutropenia
- Preclinical Radiation injuries
- No development reported Reperfusion injury; Solid tumours
Most Recent Events
- 14 May 2025 Tivic Health announces intention to submit BLA to US FDA for Acute radiation syndrome
- 28 Apr 2025 Phase-I clinical trials in Neutropenia (Parenteral), prior to April 2025 (Tivic Health pipeline, April 2025)
- 22 Apr 2025 Phase-I development in Acute radiation syndrome is ongoing in USA (IM, Injection)